Skip to Main Content

National Coverage Analysis (NCA) Tracking Sheet for Autologous Stem Cell Transplantation for AL Amyloidosis (CAG-00050N)

  • Expand All
  • Collapse All

Autologous stem cell transplantation (ASCT) is a process in which stem cells are harvested from a patient’s bone marrow or peripheral blood, stored, and then transplanted back into the patient following high dose chemotherapy use to treat various malignancies. The Coverage Issues Manuel (CIM), §35-30 does not have a policy decision in regards to coverage of ASCT for AL amyloidosis. Thus, coverage NCDs are made at contractor’s discretion. HCFA must evaluate whether there is enough scientific evidence that supports the “reasonable” and “necessary” criteria for a national coverage decision.
Inpatient Hospital Services
Physicians' Services
Requestor Name(s):  Daniel Wright, M.D., Boston Medical Center
Formal Request Accepted and Review Initiated:  09/17/1999
Expected NCA Completion Date:  12/17/1999
Public Comment Period:  10/18/1999 - 11/18/1999
Decision Memo Released:  01/14/2000
Lead Analyst(s): 
  • Jackie Sheridan-Moore
September 15, 1999 Application received.
September 17, 1999 Formal request accepted for review.
January 14, 2000 Decision made limiting Medicare's current policy of contractor discretion. See Decision Memorandum dated 1/14/00.
January 27, 2000 Letter sent informing requestor of decision to limit contractor discretion.
50